2024-510950-29-00招募中3 期
A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Outpatient, Parallel-Group Study to Assess the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 126
- 试验地点
- 50
- 主要终点
- Treatment success for the treated seizure with no recurrence after 2 hours
研究概览
简要总结
Comparison of the success of a single administration of Staccato alprazolam compared with placebo both in rapidly terminating a seizure episode within 90 seconds and with no recurrence of seizure(s) up to 2 hours after investigational medicinal product (IMP) administration.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 years 至 65+ years（18-64 Years, 0-17 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •Participant must be ≥12 years of age at the Baseline/Randomization Visit - Participant must have a study caregiver ≥18 years of age at the Screening Visit; the study caregiver(s) must be a relative, partner, friend, or legally authorized representative (LAR) of the participant, or a person who provides daily care to the participant and has a significant personal relationship with the participant; the study caregiver(s) must be able to recognize and observe the participant's seizures - Participants with an established diagnosis of focal or generalized epilepsy or combined focal and generalized epilepsy with a documented history of stereotypical episodes of prolonged seizures that includes at least 1 of the following: a) Generalized seizure episodes starting with a flurry of absence seizures or myoclonic seizures with a minimum total duration of 5 minutes b) Episodes of a focal seizure with a minimum duration of 3 minutes c) Episodes of a focal seizure or a flurry of myoclonic seizures for at least 90 seconds followed by a generalized/bilateral tonic-clonic seizure with a minimum total duration of 3 minutes - Prior to the Screening Visit, participant has experienced ≥4 stereotypical episodes of prolonged seizures in the past 6 months, and the last 2 stereotypical episodes of prolonged seizures must have occurred within the 3 months prior to the Screening Visit - Participant has had a documented brain computerized tomography or magnetic resonance imaging review, performed after diagnosis of epilepsy and within the 5 years prior to the Screening Visit, that confirms the absence of a progressive neurological disorder - Participant is receiving a regimen of antiseizure medications (ASMs) that has been stable (ie, no addition or removal of ASM[s]; dose adjustments are permitted to ASM[s]; dose adjustments are not permitted for benzodiazepines) for 30 days prior to the Screening Visit - Male and female participants: a) A male participant must agree to use contraception during the Outpatient Treatment Period and for at least 7 days after investigational medicinal product (IMP) administration and refrain from donating sperm during this period b) A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies: i) Not a woman of childbearing potential (WOCBP) OR ii) A WOCBP who agrees to follow the contraceptive guidance during the Outpatient Treatment Period and for at least 30 days after IMP administration - Participant is capable of giving signed informed consent (or giving assent, where required), which includes compliance with the requirements and restrictions listed in the informed consent form (ICF), the protocol, and the individualized participant management plan (iPMP). The informed consent form (ICF), or a specific assent form, where required, will be signed and dated by minors - The participant's study caregiver(s) must be capable of giving signed informed consent), which includes compliance with the requirements and restrictions listed in the ICF, the protocol, and the individualized participant management plan (iPMP)
排除标准
- •A history of alcohol or drug use disorder - A known hypersensitivity to any components of the IMP or comparable drugs (and/or an investigational device) or to albuterol (or similar bronchospasm rescue medication) - A diagnosis of atrial fibrillation or mitral stenosis - A history of convulsive status epilepticus in the 8 weeks prior to Screening - Has nonepileptic seizures indistinguishable from qualifying epileptic seizures - Has airway hypersensitivity and/or acute respiratory signs/symptoms - Has chronic pulmonary disorder other than mild asthma and/or recent history or presence of hemoptysis or pneumothorax - Tested positive for SARS-CoV-2 and experienced moderate to severe signs/symptoms of respiratory distress needing hospitalization or outpatient treatment such as ambulatory oxygen, treatment with inhaler medications, and/or oral medications for 4 weeks or more, unless resolved at least 6 months prior to Screening - Has experienced an upper respiratory tract infection within 4 weeks or bronchitis/pneumonia within 3 months of Screening - A history or presence of acute narrow-angle glaucoma - Has a condition where oral alprazolam is contraindicated - A history or presence of long QT syndrome, a family history of sudden death due to long QT syndrome, or unexplained syncope - Is taking any drug that is a strong CYP3A4 inhibitor, including azole antifungal agents (ketoconazole and itraconazole) and nefazodone - Is taking any opioids or sedative hypnotics on a chronic basis - Is taking nonselective beta blockers on a chronic basis - Is taking pharmacotherapy for an active psychiatric disorder and changes in regimen are anticipated during the study - Has laboratory abnormality that may increase risk associated with participation or may interfere with the interpretation of study results - Has an oxygen saturation <95 % (or less than normal in regions of altitude >2500 meters) for greater than 30 seconds during Screening. In case of an out-of-range result, 1 repeat will be allowed, if out of range again, the participant will be excluded - Has >2.0x upper limit of normal (ULN) of any of the following: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or >1.0xULN total bilirubin (≥ 1.5xULN total bilirubin if known Gilbert's syndrome or >2.0xULN total bilirubin for liver impairment) -Has current unstable liver or biliary disease defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis - Has a QT interval corrected for heart rate (QTc) >450 msec (males), QTc interval >470 msec (females), or QTc interval >480 msec (participants with bundle branch block), PR interval ≥220msec, or any other electrocardiogram (ECG) abnormality i) The QTc is the QT interval corrected for heart rate according to Fridericia's formula (QTcF), either machine-read or manually over-read - A positive urine screen for drugs of abuse at Screening
研究组 & 干预措施
alprazolam
Experimental
Participants receiving alprazolam
干预措施: alprazolam (Drug)
结局指标
主要结局
Treatment success for the treated seizure with no recurrence after 2 hours
Treatment success for the treated seizure with no recurrence after 2 hours
次要结局
- Treatment success for treated seizure with no recurrence after 4 hours
- Treatment success for treated seizure with no recurrence after 6 hours
- Time from IMP administration to cessation of the treated seizure
- Frequency of respiratory treatment emergent adverse events (TEAEs)
- Number of subsequent seizure(s) up to 2 hours after IMP administration
- Time to first subsequent seizure up to 2 hours after IMP administration
研究者
UCB Cares
Scientific
UCB Biopharma
研究点 (50)
Loading locations...
相似试验
进行中（未招募）
1 期
A study to test the efficacy and safety of Staccato alprazolam in study participants 12 years of age and older with epilepsyTreatment of stereotypical prolonged seizureMedDRA version: 20.0Level: LLTClassification code 10076333Term: Prolonged seizureSystem Organ Class: 10029205 - Nervous system disordersEUCTR2021-002686-18-BGCB Biopharma SR250
进行中（未招募）
不适用
A study in adults who have ongoing asthma, using a new product combined with Montelukast.Adult subjects, 18 to 75 years of age, with persistent asthmaMedDRA version: 16.1Level: LLTClassification code 10001705Term: Allergic asthmaSystem Organ Class: 100000004855EUCTR2012-000642-35-DEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.100
进行中（未招募）
1 期
A study to test the efficacy and safety of Staccato alprazolam in study participants 12 years of age and older with epilepsyTreatment of stereotypical prolonged seizureMedDRA version: 20.0Level: LLTClassification code 10076333Term: Prolonged seizureSystem Organ Class: 100000004852EUCTR2021-002686-18-CZCB Biopharma SR200
进行中（未招募）
1 期
A study to test the efficacy and safety of Staccato alprazolam in study participants 12 years of age and older with epilepsyEUCTR2021-002686-18-DECB Biopharma SR250
终止
1 期
A study to evaluate the Safety, Tolerability, and Pharmacokinetics of AB-506 in Healthy Subjects for 28 DaysACTRN12619001255178Arbutus Biopharma Corporation28